TIDMPRM
RNS Number : 2011B
Proteome Sciences PLC
08 June 2021
8 June 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Grant of Options and PDMR/director shareholdings
Proteome Sciences announces the grant of options over new
ordinary shares of 1p each in the Company ("Ordinary Shares") under
the Company's share option schemes ("Options"). A total of
14,000,000 Options have today been issued to three directors of the
Company.
Details of the Options granted to directors are outlined in the
table below:
Name of Director Number of Options Total number
Granted of options now
held
Dr Mariola Soehngen 9,000,000 9,000,000
------------------ ----------------
Dr Ian Pike 2,500,000 2,500,000
------------------ ----------------
Mr Richard Dennis 2,500,000 2,500,000
------------------ ----------------
The Options are exercisable at the Ordinary Shares' nominal
value of 1p per Option. For Dr Mariola Soehngen these Options will
vest in three equal annual tranches on 15 September 2021, 2022 and
2023. For Dr Ian Pike and Mr Richard Dennis , the Options will vest
in three tranches as to 1,000,000 on 15 September 2021 and 2022 and
500,000 on 15 September 2023. Each Option is exercisable into one
Ordinary Share and once vested, can be exercised up until the 10th
anniversary of today's date.
The Options granted today represent approximately 4.7 per cent
of the Company's current issued share capital. In total 15,124,000
Options are now outstanding, representing approximately 5.1 per
cent of the Company's current issued share capital.
Further details and the information required in accordance with
the requirements of Article 19(3) of the EU Market Abuse Regulation
No 596/2014 are set out at the end of this announcement.
For further information:
Proteome Sciences plc Tel: +44 (0)20 7043
Dr Mariola Soehngen, Chief Executive Officer 2116
Dr Ian Pike, Chief Scientific Officer
Allenby Capital Limited (AIM Nominated Tel: +44 (0) 20 3328
Adviser & Broker) 5656
John Depasquale / Jeremy Porter
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
The below notification is made in accordance with the
requirements of the UK Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Mariola Soehngen
----------------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status: Chief Executive Officer
----------------------------------------- ----------------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- ----------------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- ----------------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- ----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
0.01 9,000,000
----------
----------------------------------------- ----------------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
Exercisable
Price: at nominal
price of
1p per share 9,000,000
----------
----------------------------------------- ----------------------------------------
e) Date of the transaction: 8 June 2021
----------------------------------------- ----------------------------------------
f) Place of the transaction: N/A
----------------------------------------- ----------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Ian Pike
----------------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status: Chief Scientific Officer
----------------------------------------- ----------------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- ----------------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- ----------------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- ----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
0.01 2,500,000
----------
----------------------------------------- ----------------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
Exercisable
* Price: at nominal
price of
1p per share 2,500,000
----------
----------------------------------------- ----------------------------------------
e) Date of the transaction: 8 June 2021
----------------------------------------- ----------------------------------------
f) Place of the transaction: N/A
----------------------------------------- ----------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Richard Dennis
----------------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status: Chief Commercial Officer
----------------------------------------- ----------------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- ----------------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- ----------------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- ----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
Exercisable
at nominal
price of
1p per share 2,500,000
----------
----------------------------------------- ----------------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
Exercisable
Price: at nominal
price of
1p per share 2,500,000
----------
----------------------------------------- ----------------------------------------
e) Date of the transaction: 8 June 2021
----------------------------------------- ----------------------------------------
f) Place of the transaction: N/A
----------------------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFVLFBFQLEBBX
(END) Dow Jones Newswires
June 08, 2021 07:54 ET (11:54 GMT)
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
